Immunotherapy Significantly Improves Merkel Cell Carcinoma-Specific Survival: A Single-Cohort Propensity...

Area of Science:

• Oncology
• Immunotherapy
• Dermatology

Background:

• Immune checkpoint inhibitors (ICI) have transformed Merkel cell carcinoma (MCC) treatment.
• Previous analyses suggest improved survival post-ICI approval, but lack detailed treatment data.
• Direct comparison of first-line ICI versus chemotherapy in MCC is needed.

Purpose of the Study:

• To compare Merkel cell carcinoma-specific survival between patients receiving first-line ICI and those receiving first-line cytotoxic chemotherapy.
• To evaluate the efficacy of ICI as a first-line treatment for MCC.

Main Methods:

• Retrospective analysis of 1,517 MCC patients from the Seattle MCC Registry.
• Matched cohort study comparing 133 patients treated with first-line ICI to 133 treated with first-line chemotherapy using propensity scores.
• Survival analysis using Kaplan-Meier and Cox proportional hazards models.

Main Results:

• Matched cohorts had comparable baseline characteristics.
• ICI therapy demonstrated significantly improved MCC-specific survival versus chemotherapy (log-rank p<0.0001).
• Five-year MCC-specific survival was 56.8% for ICI vs. 23.9% for chemotherapy; ICI remained an independent predictor of improved survival (HR 0.32).

Conclusions:

• First-line immune checkpoint inhibitor therapy is associated with substantially improved MCC-specific survival compared to cytotoxic chemotherapy.
• ICI represents a superior first-line treatment option for patients with Merkel cell carcinoma.